Back to News
Market Impact: 0.2
Pilatus Biosciences Presents New Preclinical Data at SITC 2026 Demonstrating Potential of PLT012 to Overcome Immunotherapy Resistance in Liver Cancer
Source: Business Wire
Healthcare & Biotech
Pilatus Biosciences presented preclinical data at SITC 2026 indicating PLT012 may help overcome immunotherapy resistance in liver cancer. The headline provides no efficacy figures or clinical-stage results, so the findings remain preliminary.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Halozyme falls 6% as raised guidance fails to impress investors
- Dentsply earnings missed by $0.02, revenue fell short of estimates
- US hospitals brace for tougher 2027 as coverage losses and Medicaid cuts loom
- Cigna raises annual profit forecast on strength in health services unit
- Truist raises Zimmer Biomet stock price target on robotics progress